The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) ...

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and ...

Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT) today announced that results of a clinical trial ...

Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's first "prototype" for a CRISPR therapy, based on technology invented at UC ...

Intel launches Core Ultra Series 3 “Panther Lake” on 18A at CES 2026, widening from laptops to edge AI as Qualcomm and AMD ...

Hair loss has always been emotionally loaded, but the science behind it is becoming unusually exciting. A wave of new drugs, ...

Polybion completes full-cycle venture with one of Mexico's leading pension funds while nonprofit Drip by Drip teams with Eco ...